SciBase Holding AB (SCIB) AI Stock Analysis

• Market Cap: €155.32M
• Dividend Yield: N/A
• Average Volume (3M): 222.33K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.68
• Revenue Growth: 34.78%
• EPS Growth: 26.34%
• Country: SE
• Employees: 32
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.08
• Shares Outstanding: 414,182,600
• 10 Day Avg. Volume: 301,389
• 30 Day Avg. Volume: 222,327
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €0.55
• Price Target Upside: 44.62% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 46 Neutral
• Price Target: kr0.50 ▲(31.58% Upside)

The overall score is primarily influenced by financial performance challenges, including profitability and cash flow issues, despite revenue growth and a solid equity base. Technical analysis shows a neutral trend, while valuation is negatively impacted by ongoing losses.

SciBase Holding AB Business Overview & Revenue Model

Company Description

SciBase Holding AB (publ), a medical technology company, develops and sells instruments for the detection of skin cancer and other skin conditions in Europe and internationally. Its product includes Nevisense and Nevisense Go, a point of care platform that addresses in the areas of melanoma detection, non-melanoma skin cancer detection, and skin barrier assessment. The company has a collaboration agreement with Advanced Dermatology and Cosmetic Surgery (ADCS) group. SciBase Holding AB (publ) was founded in 1998 and is headquartered in Sundbyberg, Sweden.

How the Company Makes Money

SciBase generates revenue primarily through the sale of its diagnostic devices and related services. The company's key revenue streams include the direct sale of its flagship product, Nevisense, which is used for the early detection of melanoma and other skin cancers. Additionally, SciBase earns revenue from consumables associated with the use of its devices, as well as software and support services that accompany its diagnostic solutions. The company has established partnerships with healthcare institutions and dermatology clinics, which help expand its market reach and drive sales. Furthermore, ongoing research and development efforts aim to enhance product offerings and create new revenue opportunities through potential future products and applications in the dermatology space.

SciBase Holding AB Financial Statement Overview

Summary

SciBase Holding AB shows promising revenue growth and a solid equity base with no long-term debt, which reduces financial risk. However, profitability challenges persist with negative net profit margins and ongoing cash burn, necessitating strategic improvements for operational efficiency.

Income Statement

SciBase Holding AB has shown consistent revenue growth over the years, with a notable improvement from SEK 9.52M in 2020 to SEK 29.71M in 2024. Despite this positive trend, the company struggles with profitability, evidenced by negative net profit margins and EBIT margins over the years. The gross profit margin remains relatively strong, suggesting effective cost management at the gross level. However, the persistent operating losses and negative EBITDA highlight ongoing challenges in achieving operational efficiency.

Balance Sheet

The balance sheet indicates a stable equity position with no long-term debt in 2024, which reduces financial risk. The equity ratio is strong, reflecting a solid proportion of funding from shareholders. However, the return on equity is negative due to ongoing net losses, which is a concern for investors. The declining asset base over recent years may indicate potential challenges in asset management or investment.

Cash Flow

Cash flow analysis reveals consistent negative free cash flow, indicating cash burn that is not yet offset by operational activities. The operating cash flow to net income ratio shows a close alignment, suggesting that accounting adjustments are not significantly distorting cash performance. The company has been reliant on financing activities to fund operations, as evidenced by substantial cash inflows from financing in 2024.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	34.65M	29.70M	23.25M	17.89M	11.73M	9.52M
Gross Profit	24.32M	21.08M	16.04M	11.23M	6.58M	5.00M
EBITDA	-73.12M	-57.59M	-51.83M	-39.33M	-38.58M	-32.19M
Net Income	-89.31M	-61.13M	-55.59M	-39.90M	-41.69M	-34.99M
Balance Sheet
Total Assets	52.85M	61.73M	64.33M	49.85M	85.46M	59.25M
Cash, Cash Equivalents and Short-Term Investments	23.96M	11.24M	34.12M	18.83M	65.61M	41.43M
Total Debt	577.00K	4.18M	6.80M	8.12M	2.86M	1.92M
Total Liabilities	20.55M	25.08M	21.28M	24.62M	14.66M	12.39M
Stockholders Equity	32.30M	36.65M	43.06M	25.24M	70.80M	46.86M
Cash Flow
Free Cash Flow	-75.79M	-57.81M	-52.37M	-44.85M	-40.12M	-34.16M
Operating Cash Flow	-75.49M	-57.38M	-51.98M	-44.47M	-39.50M	-33.86M
Investing Cash Flow	-210.00K	-428.00K	-383.00K	-381.00K	-526.00K	858.00K
Financing Cash Flow	56.62M	34.91M	67.68M	-2.48M	64.22M	47.90M

SciBase Holding AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.38
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SCIB, the sentiment is Negative. The current price of 0.38 is above the 20-day moving average (MA) of 0.35, above the 50-day MA of 0.37, and below the 200-day MA of 0.39, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 47.88 is Neutral, neither overbought nor oversold. The STOCH value of 67.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SCIB.

SciBase Holding AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLS.B	58 Neutral	216.88M	-3.57	-69.30%	―	57.14%	81.07%
SCIB	46 Neutral	€155.32M	―	-210.52%	―	34.78%	26.34%
ICO	44 Neutral	125.76M	-1.15	-31.22%	―	-74.09%	26.59%
LXB	37 Underperform	87.98M	-4.03	0.00%	―	163.12%	30.50%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%